|  |
| --- |
| Supplementary table 3 Univariate analysis of factors affecting cancer-specific death. |
| Variables |  | Cancer-specific mortality  |
| 5-year mortality (95%CI） |  | SHR (95%CI) | P value |
| Age (years)≤80>80 |  |  |  |  |  | 0.620 |
| 38.04 (21.84-54.11) |  | Ref |  |
| 62.50 (17.35-88.15) |  | 1.29 (0.48-3.43) |  |
| Gender |  |  |  |  |  | 0.610 |
| Female | 50.00 (2.26-88.10) |  | Ref |  |
| Male | 41.88 (25.93-57.06) |  | 0.62 (0.10-3.81) |  |
| BMI (kg/m2) |  |  |  |  |  | 0.000 |
| ≤22.77 | 23.11 (9.15-40.77) |  | Ref |  |
| >22.77 | 77.31 (41.80-92.69) |  | 3.96 (1.81-8.68) |  |
| Smoking index |  |  |  |  |  | 0.220 |
| ≤1100 | 39.42 (22.62-55.82) |  | Ref |  |
| >1100 | 55.56 (17.08-82.24) |  | 1.65 (0.74-3.65) |  |
| Performance status |  |  |  |  |  | 0.170 |
| 0/1 | 36.42 (20.21-52.84) |  | Ref |  |
| 2 | 67.50 (23.24-89.96) |  | 1.86 (0.77-4.48) |  |
| aCCI |  |  |  |  |  | 0.180 |
| ≤5 | 33.03 (12.77-55.08) |  | Ref |  |
| >5 | 50.00 (28.41-68.26) |  | 1.75 (0.77-3.97) |  |
| Comorbidity |  |  |  |  |  | 0.019 |
| No | 19.79 (4.47-42.99) |  | Ref |  |
| Yes | 56.49 (35.03-73.27) |  | 2.75 (1.18-6.42) |  |
| Location |  |  |  |  | 0.810 |
| Left lung | 43.75 (18.86-66.38) |  | Ref |  |
| Right lung | 43.05 (23.08-61.61) |  | 1.11 (0.49-2.53) |  |
| T-stage |  |  |  |  |  |  |
| T1 | 48.61 (6.23-82.91) |  | Ref |  |
| T2 | 41.99 (21.82-60.98) |  | 1.04 (0.30-3.66) | 0.950 |
| T3 | 43.06 (13.95-69.73) |  | 1.54 (0.40-5.84) | 0.530 |
| N-stage |  |  |  |  |  | 0.490 |
| N0 | 43.82 (27.66-58.89) |  | Ref |  |
| N1 | 33.33 (0.14-83.15) |  | 0.43 (0.04-7.71) |  |
| TNM-stage |  |  |  |  |  |  |
| I | 40.53 (17.28-62.84) |  | Ref |  |
| IIA | 50.00 (16.25-76.77) |  | 0.95 (0.37-2.48) | 0.920 |
| IIB | 40.83 (15.67-64.86) |  | 1.13 (0.47-2.71) | 0.780 |
| SIRI |  |  |  |  |  | 0.530 |
| ≤0.79 | 85.71 (0.00-99.96) |  | Ref |  |
| >0.79 | 39.30 (23.23-55.02) |  | 0.72 (0.26-1.99) |  |
| NLR |  |  |  |  |  | 0.340 |
| ≤2.63 | 37.61 (14.51-60.93) |  | Ref |  |
| >2.63 | 46.57 (26.23-64.64) |  | 1.45 (0.68-3.13) |  |
| PLR |  |  |  |  |  | 0.089 |
| ≤150.36 | 34.74 (16.07-54.26) |  | Ref |  |
| >150.36 | 53.53 (27.85-73.68) |  | 1.94 (0.90-4.17) |  |
| PNI |  |  |  |  |  | 0.005 |
| ≤41.1 | 50.00 (12.53-79.35) |  | Ref |  |
| >41.1 | 41.57 (24.55-57.78) |  | 0.38 (0.19-0.74) |  |
| CAR |  |  |  |  |  | 0.002 |
| ≤0.91 | 39.19 (23.09-54.96) |  | Ref |  |
| >0.91 | 66.67 (12.22-92.48) |  | 3.65 (1.61-8.24) |  |
| LCR |  |  |  |  |  | 0.066 |
| ≤0.03 | 57.14 (13.08-85.73) |  | Ref |  |
| >0.03 | 40.34 (23.80-56.33) |  | 0.42 (0.17-1.06) |  |
| RBC (10^12/L) |  |  |  |  |  | 0.380 |
| ≤4.09 | 30.42 (11.88-51.43) |  | Ref |  |
| >4.09 | 53.73 (30.55-72.22) |  | 1.40 (0.65-3.01) |  |
| Hb (g/L) |  |  |  |  |  | 0.400 |
| ≤130 | 37.19 (20.02-54.43) |  | Ref |  |
| >130 | 57.14 (23.57-80.52) |  | 1.44 (0.62-3.32) |  |
| Time from diagnosis to SBRT (days) |  |  |  |  | 0.820 |
| ≤232 | 43.50 (26.94-58.96) |  | Ref |  |
| >232 | 40.00 (3.06-78.61) |  | 1.18 (0.28-4.94) |  |
| Size (cm) |  |  |  |  |  | 0.410 |
| ≤6.4 | 48.04 (29.36-64.50) |  | Ref |  |
| >6.4 | 29.29 (6.04-58.44) |  | 0.71 (0.31-1.61) |  |
| PTV (cm3) |  |  |  |  |  | 0.070 |
| ≤57.9 | 19.35 (4.37-42.23) |  | Ref |  |
| >57.9 | 56.48 (34.96-73.31) |  | 2.09 (0.94-4.65) |  |
| BED (Gy) |  |  |  |  |  | 0.240 |
| ≤100 | 48.33 (23.90-69.11) |  | Ref |  |
| >100 | 38.68 (19.04-58.04) |  | 0.64 (0.30-1.35) |  |
| ODR: ; BMI: body mass index; aCCI: Age-adjusted Charlson Comorbidity Index; SIRI: systemic inflammation response index; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; CRP/Alb: C-reactive protein to albumin ratio; LCR: lymphocyte to C-reactive protein ratio; RBC: red blood cell count; Hb: hemoglobin; PTV: planning tumor volume; BED: biological effective dose |